SOCS1 and neoplasm: Targeting the SOCS1 SH2 structural domain with single guide RNA (sgRNA) via CRISPR/Cas9 to inactivate Socs1 in engineered T cell can enhance the reactivity of transferred T cells to cytokines and inhibit tumor growth in mice [228].